Date: 2013-03-07
Type of information:
phase: preclinical data
Announcement: results
Company: AmVac (Switzerland)
Product: RSV vaccine candidates including AMV602
Action mechanism:
Disease: prevention of respiratory infections, which are induced by RSV (respiratory syncytial virus)
Therapeutic area: Respiratory diseases - Infectious diseases
Country:
Trial details:
Latest
news: * On March 7, 2013, AmVac has announced new preclinical data on its vaccine candidate AMV602 for the prevention of infections caused by respiratory syncytial virus (RSV). Last fall, the company selected the candidate as the most promising for further development among a range of potential leads. In preclinical studies, Prof.ssa Grazia Cusi and her team at the University of Siena, Italy, have now confirmed the candidate's excellent safety and efficacy, showing that even reduced doses of AMV602 trigger effective immune protection against RSV. Moreover, they have significantly expanded the database concerning the vaccine's therapeutic mode of action. A detailed analysis of immunological parameters further substantiates its ability to activate the two mechanisms of immune defense at the same time: the humoral immune response with antibodies as key players, and the cellular immune response with macrophages, natural killer cells and specific cytotoxic T cells as effectors.
AmVac's vaccine candidate AMV602 is based on Sendai vector technology that was invented at the Max Planck Institute for Biochemistry, Martinsried, Germany and developed by AmVac.
* On October 29, 2012, AmVac AG has announced that it has made decisive progress in the development of their new RSV vaccine. The vaccine candidate is based on AmVacs innovative Sendai virus vector platform and developed for the prevention of respiratory infections, which are induced by RSV (respiratory syncytial virus).
In close cooperation with Prof.ssa Grazia Cusi and her team from the Institute of Virology at the University of Siena, Italy, AmVac has recently recorded excellent preclinical data on the efficacy and safety of its innovative RSV vaccine. The partners have successfully completed the evaluation of different vaccine types and selected a particularly promising candidate (AMV602) for further development. In relevant model systems it was shown that AMV602 induces a stable immune protection against RSV. It activates both of the body's own defense mechanisms: first, the humoral immune response, in which antibodies play a central role, and second, the cellular immune system with helper and cytotoxic T cells as the main actors.
AmVac will continue to develop its vaccine candidate AMV602 rapidly and plans to begin clinical trials before the end of 2013.
